Table 2.
Risk factors of GARFIELD-AF Dutch cohorts 1–3
| Variable | Statistics | Cohort 1 retrospective patients (n = 93) |
Cohort 1 prospective patients (n = 106) |
Cohort 2 (n = 412) |
Cohort 3 (n = 318) |
Total without retrospective patients (n = 836) |
|---|---|---|---|---|---|---|
| Diabetes, n (%) | Yes | 20 (21.5) | 20 (18.9) | 81 (19.7) | 58 (18.2) | 159 (19.0) |
| Smoking status, n (%) | No | 26 (41.3) | 31 (37.8) | 134 (45.0) | 127 (51.8) | 292 (46.7) |
| Ex-smoker | 26 (41.3) | 37 (45.1) | 119 (39.9) | 75 (30.6) | 231 (37.0) | |
| Current smoker | 11 (17.5) | 14 (17.1) | 45 (15.1) | 43 (17.6) | 102 (16.3) | |
| Unknown | 30 | 24 | 114 | 73 | 211 | |
| CHA2DS2-VASc score | n (missing) | 87 (6) | 103 (3) | 388 (24) | 302 (16) | 793 (43) |
| Mean (SD) | 3.0 (1.3) | 3.1 (1.5) | 3.1 (1.5) | 3.0 (1.5) | 3.0 (1.5) | |
| HAS-BLED score | n (missing) | 48 (45) | 59 (47) | 194 (218) | 161 (157) | 414 (422) |
| Mean (SD) | 1.2 (0.9) | 1.4 (1.0) | 1.3 (0.9) | 1.3 (0.9) | 1.3 (0.9) |
Data from the first three GARFIELD-AF prospective cohorts – cohort 1: Dec 2009–Oct 2011; cohort 2: Oct 2011–Jun 2013; cohort 3: Jun 2013–Jun 2014